Business

GlaxoSmithKline states that preclinical studies have confirmed the potential efficacy of sotrovimab against Omicron.

By Jaime Llinares Taboda

 

GlaxoSmithKline PLC said Tuesday that a new preclinical study showed that its sotrovimab antibody retained its activity against the omicron coronavirus mutant.

A British pharmaceutical giant said sotrovimab retains in vitro activity against the fully known omicron peplomer.

These findings are based on the first preclinical data provided last week and show that the antibody remains active against all tested mutant strains of concern.

“These preclinical data indicate that our monoclonal antibodies may be effective against the latest variant, Omicron, and all other variant of concern previously defined by WHO. increase. [World Health Organization]And look forward to discussing these outcomes with regulators around the world. “

 

Write a letter to Jaime Llinares Taboada (jaime.llinares@wsj.com). @JaimeLlinaresT

GlaxoSmithKline states that preclinical studies have confirmed the potential efficacy of sotrovimab against Omicron.

Source link GlaxoSmithKline states that preclinical studies have confirmed the potential efficacy of sotrovimab against Omicron.

Back to top button